{'52WeekChange': -0.057835817,
 'SandP52WeekChange': 0.0644362,
 'address1': '10 Post Office Square',
 'address2': 'Suite 1000 South',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 32,
 'askSize': 1200,
 'averageDailyVolume10Day': 126262,
 'averageVolume': 88117,
 'averageVolume10days': 126262,
 'beta': 1.876518,
 'beta3Year': None,
 'bid': 24.71,
 'bidSize': 1000,
 'bookValue': 7.573,
 'category': None,
 'circulatingSupply': None,
 'city': 'Boston',
 'companyOfficers': [],
 'country': 'United States',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 26.78,
 'dayLow': 24.98,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': None,
 'enterpriseToEbitda': -3.293,
 'enterpriseToRevenue': 21.916,
 'enterpriseValue': 232637392,
 'exDividendDate': None,
 'exchange': 'NMS',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fiftyDayAverage': 26.248285,
 'fiftyTwoWeekHigh': 31.5,
 'fiftyTwoWeekLow': 11.26,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 11749951,
 'forwardEps': -5.86,
 'forwardPE': -4.3088737,
 'fromCurrency': None,
 'fullTimeEmployees': 55,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'heldPercentInsiders': 0.06458,
 'heldPercentInstitutions': 0.71348,
 'industry': 'Biotechnology',
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1577750400,
 'lastMarket': None,
 'lastSplitDate': 1478217600,
 'lastSplitFactor': '1:30',
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/albireopharma.com',
 'longBusinessSummary': 'Albireo Pharma, Inc., a biopharmaceutical company, '
                        'focuses on the development and commercialization of '
                        'novel bile acid modulators to treat orphan pediatric '
                        'liver diseases and gastrointestinal disorders. Its '
                        'lead product candidate is odevixibat, an ileal bile '
                        'acid transporter (IBAT) inhibitor that is in phase '
                        'III clinical trial for treating patients with '
                        'progressive familial intrahepatic cholestasis, as '
                        'well as for treating biliary atresia, alagille '
                        'syndrome, and other cholestatic liver diseases. The '
                        'company is also developing Elobixibat for the '
                        'treatment of chronic constipation and other '
                        'functional diseases, and nonalcoholic '
                        'steatohepatitis; and A3384 for the treatment of '
                        'gastrointestinal diseases. It has a license agreement '
                        'with EA Pharma for the development and '
                        'commercialization of elobixibat. Albireo Pharma, Inc. '
                        'is headquartered in Boston, Massachusetts.',
 'longName': 'Albireo Pharma, Inc.',
 'market': 'us_market',
 'marketCap': 378232384,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_41133462',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1585612800,
 'navPrice': None,
 'netIncomeToCommon': -77548000,
 'nextFiscalYearEnd': 1640908800,
 'open': 26.07,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': None,
 'phone': '857 254 5555',
 'previousClose': 26.26,
 'priceHint': 2,
 'priceToBook': 3.3342137,
 'priceToSalesTrailing12Months': 35.631878,
 'profitMargins': 0,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 26.78,
 'regularMarketDayLow': 24.98,
 'regularMarketOpen': 26.07,
 'regularMarketPreviousClose': 26.26,
 'regularMarketPrice': 26.07,
 'regularMarketVolume': 74043,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 14979500,
 'sharesPercentSharesOut': 0.0279,
 'sharesShort': 418340,
 'sharesShortPreviousMonthDate': 1590710400,
 'sharesShortPriorMonth': 249028,
 'shortName': 'Albireo Pharma, Inc.',
 'shortPercentOfFloat': 0.0318,
 'shortRatio': 4.58,
 'startDate': None,
 'state': 'MA',
 'strikePrice': None,
 'symbol': 'ALBO',
 'threeYearAverageReturn': None,
 'toCurrency': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': -5.979,
 'twoHundredDayAverage': 23.083237,
 'volume': 74043,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://www.albireopharma.com',
 'yield': None,
 'ytdReturn': None,
 'zip': '02109'}